Acrobiosystems Co.,Ltd. (SHE:301080)
39.67
-0.41 (-1.02%)
At close: Jun 2, 2026
Acrobiosystems Revenue
Acrobiosystems had revenue of 235.59M CNY in the quarter ending March 31, 2026, with 26.33% growth. This brings the company's revenue in the last twelve months to 887.21M, up 29.42% year-over-year. In the year 2025, Acrobiosystems had annual revenue of 838.12M with 29.94% growth.
Revenue (ttm)
887.21M
Revenue Growth
+29.42%
P/S Ratio
7.48
Revenue / Employee
958.11K
Employees
926
Market Cap
6.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 838.12M | 193.10M | 29.94% |
| Dec 31, 2024 | 645.02M | 101.37M | 18.65% |
| Dec 31, 2023 | 543.65M | 69.22M | 14.59% |
| Jan 1, 2023 | 474.43M | 89.44M | 23.23% |
| Jan 1, 2022 | 384.99M | 138.67M | 56.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 3.61B |
| Xiangxue Pharmaceutical | 1.60B |
| Nanjing Vazyme Biotech | 1.41B |
| Shanghai Medicilon | 1.26B |
| Chengdu Kanghua Biological Products | 1.20B |
| Wuhan Keqian Biology Co.,Ltd | 932.09M |
| Sino Biological,Inc. | 727.69M |
| Jiangsu Aidea Pharmaceutical Group | 699.33M |